Viksnins Harris Padys Malen LLP
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
ARDELYX, INC.
A A A A A A A A A A
A61K A61K A61K A61K A61K A61K A61K A61K A61K A61K
inventional inventional inventional inventional inventional inventional inventional additional additional inventional
Irina Dean Michael Robert Christopher Noah Jason Gustaf Ying Matthew Andrew Jeffrey W.
Dotsenko Dragoli Leadbetter Carreras Bell Lewis He Siegel King Jacobs